Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Albertans may see more and less-expensive varieties of Ozempic on the market soon, after a patent on the drug expired two weeks ago. Ozempic has made headlines in recent years as a popular weight-loss ...

British Columbians could soon have access to cheaper versions of injectable diabetes and obesity drugs. Health Canada is reviewing nine submissions for generic versions of semaglutide, a prescription ...

The big medical news of 2026 is about the big blockbuster drug of 2025. Semaglutide (a.k.a. Ozempic, a.k.a. Wegovy) is now off patent in Canada. In the U.S. and the rest of the world, patent ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Ozempic, pictured in ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...

Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...

The Food and Drug Administration said it will take steps to speed up the process of developing generic versions of complex biological drugs, in a bid to increase cheaper competition for expensive ...

Forbes contributors publish independent expert analyses and insights. The U.S. spent $722.5 billion on pharmaceuticals in 2023. Although brand-name drugs consume four out of every 5 dollars America ...

President Trump said he expects to reach pricing deals with more drug companies following the Pfizer announcement. Photo: Win McNamee/Getty Images WASHINGTON—The Trump administration said it isn’t ...